Brokers Set Expectations for PLRX FY2026 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Pliant Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($1.34) per share for the year. Cantor Fitzgerald currently has a "Neutral" rating on the stock. The consensus estimate for Pliant Therapeutics' current full-year earnings is ($3.64) per share.

Several other research firms also recently issued reports on PLRX. Leerink Partners downgraded shares of Pliant Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $33.00 to $2.00 in a report on Monday, March 3rd. Wells Fargo & Company decreased their price target on shares of Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating for the company in a report on Tuesday, March 4th. Royal Bank of Canada lowered their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating on the stock in a research report on Tuesday, March 4th. Needham & Company LLC restated a "hold" rating and set a $10.00 target price on shares of Pliant Therapeutics in a research note on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday, March 18th. Twelve investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Pliant Therapeutics has an average rating of "Hold" and an average target price of $13.31.

Pliant Therapeutics Stock Performance

PLRX stock traded down $0.09 during midday trading on Tuesday, hitting $1.38. 561,209 shares of the company traded hands, compared to its average volume of 1,118,777. Pliant Therapeutics has a twelve month low of $1.10 and a twelve month high of $16.10. The stock has a market capitalization of $84.71 million, a price-to-earnings ratio of -0.41 and a beta of 1.35. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The business has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $5.74.

Institutional Trading of Pliant Therapeutics

Several large investors have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in Pliant Therapeutics during the 1st quarter worth $1,642,000. Jane Street Group LLC raised its position in shares of Pliant Therapeutics by 1,270.0% during the first quarter. Jane Street Group LLC now owns 136,716 shares of the company's stock worth $185,000 after acquiring an additional 148,401 shares during the last quarter. Woodline Partners LP raised its position in shares of Pliant Therapeutics by 1,875.0% during the first quarter. Woodline Partners LP now owns 2,514,084 shares of the company's stock worth $3,394,000 after acquiring an additional 2,386,789 shares during the last quarter. Voleon Capital Management LP acquired a new position in shares of Pliant Therapeutics during the first quarter valued at $97,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Pliant Therapeutics by 6.5% in the first quarter. Goldman Sachs Group Inc. now owns 475,877 shares of the company's stock valued at $642,000 after acquiring an additional 29,177 shares during the last quarter. Institutional investors own 97.30% of the company's stock.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.